Most of the time, a company's share price rises when there is acquisition news, especially if the acquisition adds a hefty premium to the original share price. Monsanto (MON) was trading around 107-108 last week before news broke that it has accepted an offer from Bayer's which would effective acquire MON at $128 a share. So far, price action reflects doubt instead of excitement.MON Daily Chart 9/19(click to enlarge)Breakout to the downside:- I was anticipating a bullish breakout above 109. - MON was bullish in April and May before consolidating. - 109 was the consolidation resistance since July. A break would have exposed the high on the year around 114, with upward pressure towards 128.- The failure to break above 109 revealed the markets doubts. A break below 104 and a rising trendline revealed even more shakiness around this deal. - MON has now opened down side risk to 100-100.50, then the 95.90-96 area. It comes as no surprise that there will be regulatory issues when a behemoth is acquired by another giant. Here's a piece from Seeking Alpha. Investors' reaction to Bayer's announced acquisition of Monsanto for $128 a share in cash was so poor that Monsanto shares are trading almost $25 below the announced acquisition price.Investors' poor response to such acquisition recognizes the battle each of the companies face with respect to objections to such acquisition by antitrust regulators.Antitrust regulators and farmers are rightly concerned that the consolidation of the major agricultural companies will increase industry profits but increase farmer/consumer costs as well.If Bayer/Monsanto, Dow Chemical/DuPont and ChemChina/Syngenta merge, 3 companies would control 70 percent of the global pesticide market and 80 percent of the U.S. corn-seed market.We believe antitrust regulators will block Bayer's acquisition of Monsanto, but potential Monsanto investors will still benefit from long-term population/wealth trends favoring the company.We have never seen an acquisition announcement where the acquisition target's shares dropped upon such announcement and continued to drop in the following days. Welcome to the announced all-cash acquisition by Bayer AG (OTCPK:BAYRY) of Monsanto (NYSE:MON) for $66 billion, or $128 a share, that BAYRY expects to close at the end of 2017. Investors' poor response to such announced acquisition recognizes the long uphill battle each of the companies face with respect to objections to such acquisition by European and American antitrust regulators. BAYRY's announced acquisition of MON is part of a series of industry consolidation to fight off weak fundamentals in the global agricultural economy. Dow Chemical (NYSE:DOW), for example, is facing intense regulatory scrutiny in the U.S. and Europe for the $130 billion merger between itself and DuPont (NYSE:DD). As the major companies in the agricultural industry attempt to consolidate, however, consumers and farmers have argued that a consolidation of the major agricultural companies will decrease research and development by the remaining companies and will result in increased prices for consumers. (Seeking Alpha)